Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;27(2):225-228.
doi: 10.1038/s41591-020-1124-9. Epub 2020 Oct 20.

A global survey of potential acceptance of a COVID-19 vaccine

Jeffrey V Lazarus  1 , Scott C Ratzan  2 , Adam Palayew  3 , Lawrence O Gostin  4 , Heidi J Larson  5 , Kenneth Rabin  2 , Spencer Kimball  6 , Ayman El-Mohandes  2
Affiliations

A global survey of potential acceptance of a COVID-19 vaccine

Jeffrey V Lazarus et al. Nat Med. 2021 Feb.

Erratum in

Abstract

Several coronavirus disease 2019 (COVID-19) vaccines are currently in human trials. In June 2020, we surveyed 13,426 people in 19 countries to determine potential acceptance rates and factors influencing acceptance of a COVID-19 vaccine. Of these, 71.5% of participants reported that they would be very or somewhat likely to take a COVID-19 vaccine, and 48.1% reported that they would accept their employer's recommendation to do so. Differences in acceptance rates ranged from almost 90% (in China) to less than 55% (in Russia). Respondents reporting higher levels of trust in information from government sources were more likely to accept a vaccine and take their employer's advice to do so.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Extended Data Fig. 1
Extended Data Fig. 1. ‘If a COVID-19 vaccine is proven safe and effective and is available, I will take it’.
Numbers above the bars represent the percent of respondents in each country who responded positively to the question ‘If a COVID-19 vaccine is proven safe and effective and is available, I will take it’.
See this image and copyright information in PMC

Comment in

References

    1. MacDonald NE. & SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33:4161–4164. doi: 10.1016/j.vaccine.2015.04.036. - DOI - PubMed
    1. Karafillakis E, Larson HJ. & ADVANCE Consortium. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine. 2017;35:4840–4850. doi: 10.1016/j.vaccine.2017.07.061. - DOI - PubMed
    1. Cobos Muñoz D, Monzón Llamas L, Bosch-Capblanch X. Exposing concerns about vaccination in low- and middle-income countries: a systematic review. Int. J. Public Health. 2015;60:767–780. doi: 10.1007/s00038-015-0715-6. - DOI - PubMed
    1. European Parliament. European Parliament resolution of 19 April 2018 on vaccine hesitancy and drop in vaccination rates in Europe (2017/2951 RSP). https://www.europarl.europa.eu/doceo/document/TA-8-2018-0188_EN.pdf (2018).
    1. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine. 2014;32:2150–2159. doi: 10.1016/j.vaccine.2014.01.081. - DOI - PubMed

Publication types

Substances